Published in J Urol on September 01, 2005
Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst (2006) 6.02
Impact of common medications on serum total prostate-specific antigen levels: analysis of the National Health and Nutrition Examination Survey. J Clin Oncol (2010) 3.13
Calibrating disease progression models using population data: a critical precursor to policy development in cancer control. Biostatistics (2010) 1.42
Individualized estimates of overdiagnosis in screen-detected prostate cancer. J Natl Cancer Inst (2014) 1.04
Prostate cancer incidence among finasteride and alpha-blocker users in the Finnish Prostate Cancer Screening Trial. Br J Cancer (2009) 0.94
Differentiation of lethal and non lethal prostate cancer: PSA and PSA isoforms and kinetics. Asian J Androl (2012) 0.92
Projecting Benefits and Harms of Novel Cancer Screening Biomarkers: A Study of PCA3 and Prostate Cancer. Cancer Epidemiol Biomarkers Prev (2015) 0.88
False-positive screening results in the Finnish prostate cancer screening trial. Br J Cancer (2010) 0.87
Optimization of thiazole analogues of resveratrol for induction of NAD(P)H:quinone reductase 1 (QR1). Bioorg Med Chem (2012) 0.87
A Review on the Clinical Utility of PSA in Cancer Prostate. Indian J Surg Oncol (2012) 0.80
Associations Between Serum Vitamin D and Adverse Pathology in Men Undergoing Radical Prostatectomy. J Clin Oncol (2016) 0.79
Role of 5 alpha-reductase inhibitors in the management of prostate cancer. Clin Interv Aging (2006) 0.77
Re: Long-term effects of finasteride on prostate specific antigen levels: results from the Prostate Cancer Prevention Trial. J Urol (2006) 0.77
Deriving benefit of early detection from biomarker-based prognostic models. Biostatistics (2012) 0.75
Prospective investigation of change in the prostate-specific antigens after various urologic procedures. Clin Interv Aging (2015) 0.75
Use of thiazolidinediones does not affect prostate-specific antigen levels in men with diabetes. Cancer Epidemiol Biomarkers Prev (2009) 0.75
Trends and co-trends of prostate-specific antigen and body mass index in a screened population. Urology (2011) 0.75
Clinical pearls in men's health. Mayo Clin Proc (2010) 0.75
Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med (2010) 29.75
The influence of finasteride on the development of prostate cancer. N Engl J Med (2003) 24.45
Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med (2004) 15.10
Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA (2008) 13.35
The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med (2007) 12.23
Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA (2011) 11.02
Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial. J Natl Cancer Inst (2013) 10.30
Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst (2006) 9.91
Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst (2002) 9.45
Early detection of prostate cancer: AUA Guideline. J Urol (2013) 9.14
Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med (2014) 8.21
Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med (2013) 7.95
Long-term survival of participants in the prostate cancer prevention trial. N Engl J Med (2013) 7.53
Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA (2005) 6.50
American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin (2010) 6.45
Erectile dysfunction and subsequent cardiovascular disease. JAMA (2005) 6.22
Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med (2013) 6.17
Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist (2007) 6.03
Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med (2012) 5.87
Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst (2004) 5.84
An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection. J Natl Cancer Inst (2011) 5.73
Overdiagnosis and overtreatment in cancer: an opportunity for improvement. JAMA (2013) 5.56
Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst (2005) 5.10
Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol (2011) 5.01
Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst (2007) 4.64
Integrating the predictiveness of a marker with its performance as a classifier. Am J Epidemiol (2007) 4.59
Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol (2007) 4.59
Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood (2008) 4.41
Use of recovery biomarkers to calibrate nutrient consumption self-reports in the Women's Health Initiative. Am J Epidemiol (2008) 4.28
Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev (2006) 4.02
Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach. Cancer Prev Res (Phila) (2008) 3.99
Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems. Am J Respir Crit Care Med (2010) 3.83
Mortality after radical prostatectomy or external beam radiotherapy for localized prostate cancer. J Natl Cancer Inst (2013) 3.81
Effect of age, tumor risk, and comorbidity on competing risks for survival in a U.S. population-based cohort of men with prostate cancer. Ann Intern Med (2013) 3.74
Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst (2006) 3.62
Ureteroenteric anastomotic strictures after radical cystectomy-does operative approach matter? J Urol (2012) 3.30
Comparative effectiveness of prostate cancer treatments: evaluating statistical adjustments for confounding in observational data. J Natl Cancer Inst (2010) 3.24
Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). J Natl Cancer Inst (2005) 2.99
Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794. J Clin Oncol (2007) 2.97
Estimated impact of the Prostate Cancer Prevention Trial on population mortality. Cancer (2005) 2.91
Factors associated with satisfaction with prostate cancer care: results from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). BJU Int (2012) 2.88
Adult-onset immunodeficiency in Thailand and Taiwan. N Engl J Med (2012) 2.87
GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity. Blood (2013) 2.82
Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study. Clin Cancer Res (2013) 2.70
Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer Causes Control (2007) 2.69
The prostate cancer conundrum revisited: treatment changes and prostate cancer mortality declines. Cancer (2012) 2.61
Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study. J Clin Oncol (2011) 2.57
Prospective evaluation of operating characteristics of prostate cancer detection biomarkers. J Urol (2010) 2.54
Pathologic characteristics of cancers detected in The Prostate Cancer Prevention Trial: implications for prostate cancer detection and chemoprevention. Cancer Prev Res (Phila) (2008) 2.43
Why do men choose one treatment over another?: a review of patient decision making for localized prostate cancer. Cancer (2006) 2.42
The association between diffusion of the surgical robot and radical prostatectomy rates. Med Care (2011) 2.38
SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer. Clin Chem (2007) 2.38
Castration-resistant prostate cancer: AUA Guideline. J Urol (2013) 2.36
A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol Biomarkers Prev (2010) 2.36
Immediate effects of the initial FDA notification on the use of surgical mesh for pelvic organ prolapse surgery in medicare beneficiaries. Neurourol Urodyn (2012) 2.35
Impact of cryopreservation on tetramer, cytokine flow cytometry, and ELISPOT. BMC Immunol (2005) 2.31
Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. Lancet Oncol (2013) 2.29
Idiopathic CD4+ lymphocytopenia: natural history and prognostic factors. Blood (2008) 2.27
What if I don't treat my PSA-detected prostate cancer? Answers from three natural history models. Cancer Epidemiol Biomarkers Prev (2011) 2.25
Race/ethnicity, obesity, health related behaviors and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. J Urol (2007) 2.24
Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias. Clin Chem (2007) 2.23
Access to information sources and treatment considerations among men with local stage prostate cancer. Urology (2009) 2.15
Pharmacological approaches to reducing the risk of prostate cancer. Eur Urol (2009) 2.09
Predicting risk of prostate cancer in men receiving finasteride: effect of prostate volume, number of biopsy cores, and American Urological Association symptom score. Urology (2013) 2.06
Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach. Med Decis Making (2008) 2.06
Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev (2009) 2.06
Breast cancer incidence rates in U.S. women are no longer declining. Cancer Epidemiol Biomarkers Prev (2011) 2.06
External validation of the Prostate Cancer Prevention Trial risk calculator in a screened population. Urology (2006) 2.05
Biomarker-calibrated energy and protein consumption and increased cancer risk among postmenopausal women. Am J Epidemiol (2009) 1.98
Health related quality of life after radical cystectomy and urinary diversion for bladder cancer: a systematic review and critical analysis of the literature. J Urol (2005) 1.97
Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection. J Urol (2007) 1.97
Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial. J Clin Oncol (2007) 1.95
The prostate cancer prevention trial: design, biases and interpretation of study results. J Urol (2006) 1.91
Tuberculosis risk factors and mortality for HIV-infected persons receiving antiretroviral therapy in South Africa. AIDS (2010) 1.90
Finasteride reduces the risk of incident clinical benign prostatic hyperplasia. Eur Urol (2012) 1.89
Limitations of basing screening policies on screening trials: The US Preventive Services Task Force and Prostate Cancer Screening. Med Care (2013) 1.88
Natural history of autoimmune lymphoproliferative syndrome associated with FAS gene mutations. Blood (2014) 1.88
Antisense phosphorodiamidate morpholino oligomers targeted to an essential gene inhibit Burkholderia cepacia complex. J Infect Dis (2010) 1.84
National trends in the use of partial nephrectomy: a rising tide that has not lifted all boats. J Urol (2012) 1.84
A meta-analysis identifies new loci associated with body mass index in individuals of African ancestry. Nat Genet (2013) 1.82
Urine metabolomics analysis for kidney cancer detection and biomarker discovery. Mol Cell Proteomics (2008) 1.78
Volume outcomes of cystectomy--is it the surgeon or the setting? J Urol (2012) 1.77
Association between socioeconomic status (SES) and lower urinary tract symptom (LUTS) severity among black and white men. J Gen Intern Med (2011) 1.76
Inhaled amikacin for treatment of refractory pulmonary nontuberculous mycobacterial disease. Ann Am Thorac Soc (2014) 1.76
Radical cystectomy with extended lymphadenectomy: evaluating separate package versus en bloc submission for node positive bladder cancer. J Urol (2007) 1.74